SCHEMBL26617283

SCHEMBL26617283

O=C(NCc1cccc[n+]1[O-])c1cccc(Br)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ NPC1 O15118 2/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ LMNA P02545 2/20 0.49
▸ HPGD P15428 1/20 0.49
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ MAPT P10636 4/20 0.46
▸ ALDH1A1 P00352 3/20 0.45
▸ GAA P10253 2/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ TP53BP1 Q12888 1/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ HDAC2 Q92769 1/20 0.45
▸ HDAC8 Q9BY41 1/20 0.45
▸ HDAC6 Q9UBN7 1/20 0.45
▸ ALOX5 P09917 1/20 0.43
▸ FLT1 P17948 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26617213 0.84 EPHX2 (0.56) HPGDALDH1A1SMN1; SMN2HDAC2HDAC8
SCHEMBL30613556 0.84 BCHE (0.40) HPGDALDH1A1SMN1; SMN2ALOX5
SCHEMBL26617195 0.81 EPHX2 (0.47) NPC1RAB9AHPGDMEN1KMT2A
SCHEMBL26617185 0.80 DRD4 (0.49) NPC1RAB9AHPGDMEN1KMT2A
SCHEMBL26617194 0.80 RXRA (0.48) HDAC8
SCHEMBL26617216 0.80 EPHX2 (0.49) NPC1RAB9AALDH1A1SMN1; SMN2POLB
SCHEMBL26704136 0.80 MEN1 (0.50) MEN1KMT2AHDAC8
SCHEMBL26617239 0.80 HPGD (0.51) LMNAHPGDMEN1KMT2AMAPT
SCHEMBL26617202 0.79 KAT6A (0.48) NPC1RAB9ALMNAHPGDMEN1
SCHEMBL26617252 0.79 AURKA (0.52) HPGDHDAC8FLT1FLT4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250333383-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2025-10-30 — — US disclosed
EP-4514777-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK Biopharmaceuticals Co., Ltd. (KR) 2025-03-05 — — EP disclosed
WO-2023211195-A1 N-OXIDE COMPOUNDS AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-11-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250333383-A1 N-OXIDE COMPOUNDS AND USE THEREOF SCNN1B, SCN1B, SCN2B L3MBTL1 4726/4885NPC1 371/4885RAB9A 1715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback